The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing possible new treatments and furthering knowledge about the disease course.

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

Rituximab (Rituxan) provides consistently better relapse outcomes than natalizumab (Tysabri) in patients with multiple sclerosis (MS), new research suggests. Findings from a real-world "comparative ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...

Prenatal and early life sun exposure was associated with lower risk for relapse in children with pediatric-onset multiple sclerosis (MS), a new prospective cohort study showed. At least 30 minutes of ...

Please provide your email address to receive an email when new articles are posted on . Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At ...

Immunoglobulin G oligoclonal bands in CSF are highly prevalent in MS and CIS, with positive status associated with a significantly earlier age of disease onset.

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...